Huang Huang, Dunne Michael, Lo John, Jaffray David A, Allen Christine
Leslie Dan Faculty of Pharmacy, Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Mol Imaging. 2013 May;12(3):148-60.
The use of multimodal imaging as a tool to assess the in vivo pharmacokinetics and biodistribution of nanocarriers is important in understanding the nature of their in vivo transport. The current study reports the development of a nano-sized liposomal computed tomographic (CT)/optical imaging probe carrying iohexol and Cy5.5 and its use in micro-CT and optical imaging to quantitatively assess the whole-body (macroscopic), intratumoral, and microscopic distribution over a period of 8 days. These multimodal liposomes have a vascular half-life of 30.3 ± 8.9 hours in mice bearing subcutaneous H520 non-small cell lung cancer tumors, with the maximum liposome accumulation in tumor achieved 48 hours postinjection. The in vivo liposome distribution and stability were quantitatively assessed using both micro-CT and fluorescence molecular tomography. The combination of CT and optical imaging enables visualization of the liposomes at the whole-body, tumor, and cellular scales with high sensitivity. Such noninvasive tracking of therapeutic vehicles at the macro- and microscale is important for informed and rational development of novel nanocarrier systems.
使用多模态成像作为评估纳米载体体内药代动力学和生物分布的工具，对于理解其体内转运的性质很重要。当前的研究报告了一种携带碘海醇和Cy5.5的纳米尺寸脂质体计算机断层扫描（CT）/光学成像探针的研发，以及其在微型CT和光学成像中的应用，用于在8天时间内定量评估全身（宏观）、肿瘤内和微观分布。这些多模态脂质体在携带皮下H520非小细胞肺癌肿瘤的小鼠体内的血管半衰期为30.3±8.9小时，注射后48小时肿瘤内脂质体积累达到最大值。使用微型CT和荧光分子断层扫描对体内脂质体分布和稳定性进行了定量评估。CT和光学成像的结合能够以高灵敏度在全身、肿瘤和细胞尺度上可视化脂质体。在宏观和微观尺度上对治疗载体进行这种非侵入性追踪，对于新型纳米载体系统的明智和合理开发很重要。
